BSE Live
Jan 01, 09:28Prev. Close
1181.20
Open Price
1184.95
Bid Price (Qty.)
1176.40 (1)
Offer Price (Qty.)
1177.30 (2)
NSE Live
Jan 01, 09:28Prev. Close
1183.00
Open Price
1190.00
Bid Price (Qty.)
1176.50 (234)
Offer Price (Qty.)
1177.00 (37)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 27.86 | 26.88 | 26.88 | 26.67 | 26.63 | |
| Total Share Capital | 27.86 | 26.88 | 26.88 | 26.67 | 26.63 | |
| Reserves and Surplus | 1,801.22 | 1,214.38 | 1,097.14 | 859.32 | 788.20 | |
| Total Reserves and Surplus | 1,801.22 | 1,214.38 | 1,097.14 | 859.32 | 788.20 | |
| Total Shareholders Funds | 1,829.08 | 1,241.26 | 1,124.02 | 885.99 | 814.83 | |
| Minority Interest | 4.33 | 3.15 | 3.19 | 3.54 | 2.43 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 938.89 | 1,266.25 | 1,236.09 | 1,451.92 | 823.63 | |
| Deferred Tax Liabilities [Net] | 95.35 | 79.04 | 73.34 | 68.19 | 72.56 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 1,034.24 | 1,345.29 | 1,309.43 | 1,520.11 | 896.19 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,215.67 | 1,066.72 | 610.94 | 626.22 | 549.44 | |
| Trade Payables | 604.40 | 514.77 | 463.17 | 420.51 | 386.13 | |
| Other Current Liabilities | 68.40 | 28.69 | 91.43 | 23.73 | 22.89 | |
| Short Term Provisions | 35.19 | 26.59 | 32.30 | 26.38 | 17.51 | |
| Total Current Liabilities | 1,923.66 | 1,636.77 | 1,197.84 | 1,096.84 | 975.97 | |
| Total Capital And Liabilities | 4,791.31 | 4,226.47 | 3,634.48 | 3,506.50 | 2,689.46 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,566.32 | 1,280.20 | 1,191.55 | 1,048.28 | 990.97 | |
| Intangible Assets | 144.53 | 118.57 | 108.75 | 104.33 | 92.78 | |
| Capital Work-In-Progress | 570.08 | 536.30 | 214.55 | 218.71 | 149.74 | |
| Fixed Assets | 2,280.93 | 1,935.07 | 1,514.85 | 1,371.32 | 1,233.49 | |
| Non-Current Investments | 0.28 | 0.26 | 60.43 | 0.27 | 0.28 | |
| Deferred Tax Assets [Net] | 4.17 | 2.17 | 0.12 | 0.00 | 0.01 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 2,285.38 | 1,937.50 | 1,575.40 | 1,371.59 | 1,233.78 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 1,102.45 | 877.63 | 795.03 | 654.40 | 471.81 | |
| Trade Receivables | 956.01 | 889.76 | 665.01 | 626.11 | 582.23 | |
| Cash And Cash Equivalents | 72.83 | 127.65 | 282.57 | 582.46 | 201.93 | |
| Short Term Loans And Advances | 373.30 | 393.93 | 316.47 | 271.94 | 199.71 | |
| OtherCurrentAssets | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 2,505.93 | 2,288.97 | 2,059.08 | 2,134.91 | 1,455.68 | |
| Total Assets | 4,791.31 | 4,226.47 | 3,634.48 | 3,506.50 | 2,689.46 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 165.09 | 93.41 | 187.86 | 63.58 | 114.56 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 17.35 | 17.35 | 17.35 | 17.35 | 17.35 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.05 | 0.02 | 0.03 | 0.03 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 0.24 | 0.24 | 60.39 | 0.24 | 0.28 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL